Skip to main content
TipRanks
Go Ultimate75% OFF

Wanbury Limited (WANBURY) AI Stock Analysis

0 Followers
IN:WANBURY

Wanbury Limited

(NSE:WANBURY)

Select Model
Rating:49Neutral
Price Target:INR 174.00▼(-10.15% Downside)
Action:reiterated
Date:10/01/26

The score is constrained primarily by weak financial quality (poor cash generation and high leverage despite improved reported profitability) and bearish technical momentum (below major moving averages with negative MACD). A relatively modest P/E provides some valuation support but is not enough to offset the cash-flow and trend risks.

Positive Factors
Diversified pharmaceutical operationsWanbury operates across APIs and finished dosage formulations, serving both domestic and export markets. This broader pharmaceutical model provides multiple product and channel avenues for revenue generation, while its branded, generic, distribution, and institutional activities can support business continuity across demand segments.
Negative Factors
Weak cash conversionMinimal operating cash flow despite healthy FY2026 net income shows that reported profits are not currently translating into cash. Deeply negative free cash flow can increase reliance on external funding and restrict the company’s ability to finance growth, absorb execution setbacks, or reduce debt internally.

Wanbury Limited (WANBURY) vs. iShares MSCI India ETF (INDA)

-40%-20%0%20%40%60%IN:WANBURY-15.14%INDA-5.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 6.76B
Dividend Yield
―
Average Volume (3M)
18.17K
Price to Earnings (P/E)
12.7
Beta (1Y)
1.50
Revenue Growth
7.45%
EPS Growth
-6.56%
Country
India
Employees
1,200
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Wanbury Limited Business Overview & Revenue Model

Company Description

Wanbury Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and commercialization of both finished drug products (formulations) and active pharmaceutical ingredients (APIs). The company's diverse range of formulatio...

Wanbury Limited Financial Statement Overview

Summary

Turnaround in profitability and steady revenue expansion support the score, but it is heavily offset by very weak cash conversion (minimal operating cash flow and deeply negative free cash flow in FY2025–FY2026) and still-elevated leverage (debt greater than equity in FY2026). Margin volatility and recent gross margin compression also add sustainability risk.

Income Statement

66Positive

Balance Sheet

50Neutral

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Jun 2023Mar 2022
Income Statement
Total Revenue6.76B6.50B6.00B5.74B4.98B5.11B
Gross Profit2.71B2.40B3.05B2.65B1.89B2.04B
EBITDA923.32M1.04B798.13M985.49M234.91M1.13B
Net Income498.37M661.35M305.30M559.56M-103.96M814.74M
Balance Sheet
Total Assets5.72B5.18B4.14B3.43B3.04B3.53B
Cash, Cash Equivalents and Short-Term Investments103.00M76.32M150.63M34.00M14.94M226.56M
Total Debt2.37B2.24B1.77B1.16B1.09B1.08B
Total Liabilities4.15B3.73B3.55B3.16B3.36B3.76B
Stockholders Equity1.57B1.44B592.72M279.41M-61.54M-234.20M
Cash Flow
Free Cash Flow0-568.35M-229.26M-134.45M71.69M308.65M
Operating Cash Flow027.76M261.02M39.78M197.97M405.23M
Investing Cash Flow0-571.12M-511.74M-166.25M-88.38M5.87M
Financing Cash Flow0518.87M257.33M145.53M-319.91M-285.85M

Wanbury Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price193.65

Price Trends

50DMA207.86Negative
100DMA247.36Negative
200DMA249.34Negative

Market Momentum

MACD-2.09Negative
RSI47.77Neutral
STOCH59.80Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WANBURY, the sentiment is Negative. The current price of 193.65 is above the 20-day moving average (MA) of 188.24, below the 50-day MA of 207.86, and below the 200-day MA of 249.34, indicating a neutral trend. The MACD of -2.09 indicates Negative momentum. The RSI at 47.77 is Neutral, neither overbought nor oversold. The STOCH value of 59.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:WANBURY.

Wanbury Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:WANBURY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:JAGSNPHARMIN:JAGSNPHARM78OutperformINR 14.27B31.90―1.84%11.71%-26.92%
IN:LINCOLNIN:LINCOLN67NeutralINR 10.46B10.87―0.35%14.25%21.11%
IN:KILITCHIN:KILITCH63NeutralINR 7.53B30.88――13.87%-17.80%
IN:ANUHPHRIN:ANUHPHR61NeutralINR 8.27B17.30―1.82%6.62%53.57%
IN:ZIMLABIN:ZIMLAB60NeutralINR 7.60B263.30――13.14%-60.77%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:WANBURYIN:WANBURY49NeutralINR 6.77B12.69――7.45%-6.56%

* General Sector Average

Performance Comparison

0%50%100%IN:WANBURYIN:JAGSNPHARMIN:KILITCHIN:LINCOLNIN:ZIMLABIN:ANUHPHRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:WANBURY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:WANBURYWanbury Limited193.65-39.25-16.85%
IN:JAGSNPHARMJagsonpal Pharmaceuticals Ltd.216.058.043.86%
IN:KILITCHKilitch Drugs (India) Limited215.4037.8321.30%
IN:LINCOLNLincoln Pharmaceuticals Ltd522.00-8.10-1.53%
IN:ZIMLABZim Laboratories Ltd.141.7067.7991.72%
IN:ANUHPHRAnuh Pharma Limited82.523.434.34%

Wanbury Limited Corporate Events

Wanbury Confirms SEBI-Compliant Dematerialisation for September Quarter

Oct 9, 2026

Wanbury Limited has reported that it has obtained a statutory confirmation from its registrar and share transfer agent Purva Sharegistry (India) Pvt. Ltd. under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the qu...

Wanbury Gains USFDA DMF Clearance for Metformin API, Bolstering Global Expansion

Jul 30, 2026

Wanbury Limited announced that it has received a “No DMF deficiency” communication from the U.S. Food and Drug Administration for multiple ANDAs that use its Metformin HCl API in different formulations, indicating full compliance of its DMF filings....

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026